scholarly journals Lipid Metabolism is the common pathologic mechanism between Type 2 Diabetes Mellitus and Parkinson's disease

2020 ◽  
Vol 17 (12) ◽  
pp. 1723-1732
Author(s):  
Xi Zhang ◽  
Yu Fan ◽  
Yuping Luo ◽  
Lingjing Jin ◽  
Siguang Li
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Metabolism ◽  
The Common

scholarly journals The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease

2020 ◽  
pp. 1-15 ◽  
Author(s):  
Julia L.Y. Cheong ◽  
Eduardo de Pablo-Fernandez ◽  
Thomas Foltynie ◽  
Alastair J. Noyce
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Type 2 Diabetes Mellitus

scholarly journals Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study

2020 ◽  
Author(s):  
Catherine S. Storm ◽  
Demis A. Kia ◽  
Mona Almramhi ◽  
Dilan Athauda ◽  
Stephen Burgess ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Type 2 Diabetes Mellitus ◽  
Brain Tissue ◽  
Mendelian Randomization ◽  
Disease Risk ◽  
Age At Onset

AbstractBackgroundExenatide is a glucagon-like peptide 1 receptor (GLP1R) agonist used in type 2 diabetes mellitus that has shown promise for Parkinson’s disease in a phase II clinical trial. Drugs with genetic evidence are more likely to be successful in clinical trials. In this study we investigated whether the genetic technique Mendelian randomization (MR) can “rediscover” the effects of exenatide on diabetes and weight, and predict its efficacy for Parkinson’s disease.MethodsWe used genetic variants associated with increased expression of GLP1R in blood to proxy exenatide, as well as variants associated with expression of DPP4, TLR4 and 15 genes thought to act downstream of GLP1R or mimicking alternative actions of GLP-1 in blood and brain tissue. Using an MR approach, we predict the effect of exenatide on type 2 diabetes risk, body mass index (BMI), Parkinson’s disease risk and several Parkinson’s disease progression markers.ResultsWe found that genetically-raised GLP1R expression in blood was associated with lower BMI and possibly type 2 diabetes mellitus risk, but not Parkinson’s disease risk, age at onset or progression. Reduced DPP4 expression in brain tissue was significantly associated with increased Parkinson’s disease risk.ConclusionsWe demonstrate the usefulness of MR using expression data in predicting the efficacy of a drug and exploring its mechanism of action. Our data suggest that GLP-1 mimetics like exenatide, if ultimately proven to be effective in Parkinson’s disease, will be through a mechanism that is independent of GLP1R in blood.

Sign in / Sign up

Export Citation Format

Share Document